Seeking Alpha

Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3...

Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3 sarcoma drug. The results correlate with positive data reported in February. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs